Arcutis Announces Positive Topline Results from ARRECTOR Pivotal Phase 3 Trial of Roflumilast Foam 0.3% in Scalp and Body Psoriasis
Study met both co-primary endpoints and all secondary endpoints. At week eight, 67.3% of individuals treated with roflumilast foam achieved Scalp-Investigator Global Assessment (S-IGA) Success compared to 28.1% of individuals treated with vehicle At week eight, 46.5% of individuals treated with roflumilast foam achieved Body-Investigator Global Assessment (B-IGA) Success compared to 20.8% of individuals treated with vehicle Once-daily roflumilast foam demonstrated a favorable safety and tolerability profile
